Wellgistics Health Expands Pharmaceutical Distribution with Tollo Health Partnership

Wellgistics Health, Inc. has announced a significant expansion of its agreement with Tollo Health. The focus is on distributing a novel dietary management food targeting muscle loss, specifically for patients using GLP-1 therapies. This development aligns with a growing market projected to reach $150 billion by 2030.

In addition, Wellgistics adds a new antiviral combination to its offerings. The inclusion of the Tollovid® supplement complements Galectovid® to address Long COVID symptoms. This marks the first natural antiviral duo addressing specific replication and immune function aspects of SARS-CoV-2.

With these initiatives, Wellgistics aims to mitigate key side effects such as muscle loss associated with GLP-1 therapies, simultaneously enhancing interest among physicians and pharmacies in these novel products.